X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (240349) 240349
Newsletter (14409) 14409
Newspaper Article (12687) 12687
Magazine Article (951) 951
Book Chapter (611) 611
Transcript (212) 212
Book / eBook (210) 210
Dissertation (207) 207
Trade Publication Article (66) 66
Conference Proceeding (65) 65
Web Resource (58) 58
Publication (39) 39
Streaming Video (38) 38
Reference (35) 35
Report (22) 22
Book Review (16) 16
Journal / eJournal (7) 7
Government Document (6) 6
Paper (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (141864) 141864
animals (97241) 97241
antibodies (79167) 79167
female (72918) 72918
male (60934) 60934
viral antibodies (59921) 59921
adult (43888) 43888
viruses (43289) 43289
virology (43283) 43283
immunology (39094) 39094
mice (35191) 35191
middle aged (33566) 33566
infections (31436) 31436
health aspects (31241) 31241
infectious diseases (29871) 29871
infection (29724) 29724
research (29019) 29019
antibodies, viral - blood (28551) 28551
proteins (25691) 25691
analysis (24152) 24152
research article (23693) 23693
microbiology (23397) 23397
antibodies, viral - analysis (23020) 23020
virus diseases (22067) 22067
adolescent (20963) 20963
cell line (19486) 19486
viral infections (18936) 18936
aged (18518) 18518
enzyme-linked immunosorbent assay (18360) 18360
molecular sequence data (18138) 18138
vaccines (17904) 17904
child (17161) 17161
antigens (17133) 17133
vaccination (16829) 16829
medicine (15333) 15333
medical research (14832) 14832
multidisciplinary sciences (14344) 14344
antibodies, viral - immunology (14079) 14079
veterinary sciences (13959) 13959
expression (13546) 13546
child, preschool (13477) 13477
amino acid sequence (13173) 13173
polymerase chain reaction (12767) 12767
infant (12606) 12606
cancer (12315) 12315
immunization (12196) 12196
risk factors (12003) 12003
medicine, research & experimental (11816) 11816
disease (11784) 11784
hiv (11733) 11733
gene expression (11543) 11543
prevalence (11356) 11356
neutralization tests (11066) 11066
dna (10939) 10939
science (10771) 10771
base sequence (10423) 10423
epidemiology (10412) 10412
diagnosis (10393) 10393
genetic aspects (10357) 10357
biotechnology & applied microbiology (10351) 10351
virus (10326) 10326
mice, inbred balb c (10255) 10255
care and treatment (10141) 10141
rna (10074) 10074
antigens, viral - immunology (9996) 9996
cells, cultured (9924) 9924
fluorescent antibody technique (9897) 9897
biology (9870) 9870
viral load (9785) 9785
time factors (9762) 9762
biochemistry & molecular biology (9673) 9673
studies (9653) 9653
young adult (9650) 9650
immunoglobulins (9610) 9610
medicine, experimental (9322) 9322
cell biology (9299) 9299
cells (9275) 9275
immune response (9257) 9257
physiological aspects (9075) 9075
hepatitis (9032) 9032
lymphocytes (8976) 8976
oncology (8939) 8939
mutation (8785) 8785
t cells (8776) 8776
virus replication (8774) 8774
cattle (8758) 8758
identification (8697) 8697
influenza (8682) 8682
immunity (8645) 8645
viral vaccines - immunology (8278) 8278
protein (8225) 8225
pregnancy (7958) 7958
children (7810) 7810
replication (7809) 7809
phylogeny (7692) 7692
immune system (7554) 7554
vaccine (7485) 7485
viral diseases (7479) 7479
genomes (7345) 7345
genotype (7264) 7264
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (104) 104
Collection Dvlpm't (Acquisitions) - Vendor file (18) 18
Online Resources - Online (16) 16
UofT at Mississauga - Stacks (14) 14
Collection Dvlpm't (Acquisitions) - Closed Orders (12) 12
UofT at Scarborough - Stacks (9) 9
New College (Ivey) - Stacks (6) 6
UTL at Downsview - May be requested (6) 6
St. Michael's College (John M. Kelly) - 2nd Floor (4) 4
Robarts - Stacks (3) 3
Trinity College (John W Graham) - Stacks (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
Engineering & Comp. Sci. - Stacks (2) 2
Gerstein Science - Circulation Desk (2) 2
University College (Laidlaw) - Stacks (2) 2
Gerstein Science - Searching (1) 1
Law (Bora Laskin) - Stacks (1) 1
OISE - Processing (1) 1
OISE - Stacks (1) 1
Providence Healthcare - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Bindery (1) 1
UofT at Scarborough - Withdrawn (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (258340) 258340
Russian (3031) 3031
Japanese (2405) 2405
German (2021) 2021
Chinese (1753) 1753
French (1401) 1401
Spanish (1168) 1168
Italian (593) 593
Polish (373) 373
Czech (305) 305
Portuguese (277) 277
Dutch (191) 191
Turkish (170) 170
Bulgarian (165) 165
Croatian (80) 80
Romanian (77) 77
Hungarian (72) 72
Slovak (69) 69
Serbian (51) 51
Danish (48) 48
Ukrainian (47) 47
Norwegian (42) 42
Swedish (42) 42
Korean (31) 31
Hebrew (18) 18
Finnish (14) 14
Arabic (11) 11
Persian (7) 7
Icelandic (3) 3
Lithuanian (3) 3
Bosnian (2) 2
Greek (1) 1
Indonesian (1) 1
Slovenian (1) 1
Thai (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature (London), ISSN 1476-4687, 2015, Volume 522, Issue 7557, pp. 487 - 491
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned(1-3... 
THERAPY | VIRUS | HIV-1 NEUTRALIZATION | GENETIC-DETERMINANTS | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | IN-VIVO | VACCINE | MICE | MONOCLONAL-ANTIBODIES | Antibodies, Neutralizing - administration & dosage | Humans | Middle Aged | Viremia - therapy | Molecular Sequence Data | Antibodies, Monoclonal - therapeutic use | Male | Case-Control Studies | HIV Envelope Protein gp120 - immunology | Young Adult | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - adverse effects | HIV Antibodies - immunology | Time Factors | HIV-1 - chemistry | Antibodies, Neutralizing - therapeutic use | Adult | Antibodies, Neutralizing - adverse effects | Female | HIV Antibodies - therapeutic use | HIV Envelope Protein gp120 - chemistry | HIV Antibodies - pharmacology | Binding Sites | Antibodies, Monoclonal - immunology | Amino Acid Sequence | Immunization, Passive - methods | HIV-1 - drug effects | HIV Infections - virology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Neutralizing - pharmacology | HIV Antibodies - administration & dosage | Viral Load - immunology | HIV-1 - immunology | Viremia - virology | Antibodies, Monoclonal - administration & dosage | HIV Infections - therapy | Viremia - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Evolution, Molecular | Viral antibodies | Virus diseases | Physiological aspects | Antibodies | HIV infection | Antigens | Immunoglobulins | Human immunodeficiency virus--HIV | Immunotherapy | Infections | Drug dosages | Binding sites | Immune system
Journal Article
Nature, ISSN 0028-0836, 08/2014, Volume 514, Issue 7524, pp. 642 - 645
To protect against human immunodeficiency virus (HIV-1) infection, broadly neutralizing antibodies (bnAbs... 
HALF-LIFE | CHALLENGE | IMMUNITY | TRANSPORT | NEUTRALIZING ANTIBODIES | HUMAN IGG1 | DENDRITIC CELLS | MULTIDISCIPLINARY SCIENCES | IN-VIVO | MONOCLONAL-ANTIBODIES | HIV-1 VACCINE | HIV Antibodies - blood | Antibodies, Neutralizing - analysis | HIV Infections - prevention & control | Immunity, Mucosal - immunology | Antibody-Dependent Cell Cytotoxicity - immunology | Half-Life | Administration, Rectal | Antibody Affinity - immunology | Male | HIV - immunology | Macaca mulatta | Antibodies, Viral - blood | Receptors, IgG - metabolism | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Antibodies, Viral - analysis | HIV - chemistry | Intestinal Mucosa - immunology | Female | Transcytosis | Simian Immunodeficiency Virus - immunology | HIV Antibodies - analysis | Mutagenesis, Site-Directed | Histocompatibility Antigens Class I - immunology | Antibody Affinity - genetics | Antibodies, Neutralizing - genetics | Binding Sites - genetics | Receptors, IgG - immunology | Rectum - immunology | Simian Acquired Immunodeficiency Syndrome - prevention & control | Animals | Receptors, Fc - immunology | Simian Acquired Immunodeficiency Syndrome - immunology | Immunization, Passive | Antibodies, Viral - immunology | HIV Envelope Protein gp160 - immunology | Mice | HIV Antibodies - genetics | Antibodies, Neutralizing - blood | Antibodies, Viral - genetics | CD4 Antigens - metabolism | Viral antibodies | Infection | Prevention | Fc receptors | Protein research | Antibodies | Primates | Research | Simian immunodeficiency virus | Health aspects | T cell receptors | Physiology | Mutation | Human immunodeficiency virus--HIV | Viral infections | Index Medicus
Journal Article
Nature (London), ISSN 1476-4687, 2014, Volume 515, Issue 7525, pp. 138 - 142
The isolation of human monoclonal antibodies is providing important insights into the specificities that underlie broad neutralization of HIV-1 (reviewed in ref. 1... 
B-CELLS | SPECIFICITIES | MULTIDISCIPLINARY SCIENCES | SERA | IMMUNODEFICIENCY-VIRUS TYPE-1 | ENV TRIMERS | VULNERABILITY | GP120 | HUMAN MONOCLONAL-ANTIBODIES | CLEAVAGE | DEPENDENT EPITOPE | Immunoglobulin Fab Fragments - ultrastructure | Antibody Specificity | Epitope Mapping | HIV Envelope Protein gp41 - immunology | Humans | AIDS Vaccines - immunology | Molecular Sequence Data | Leukocytes, Mononuclear | HIV Envelope Protein gp41 - chemistry | Virus Internalization - drug effects | Epitopes - immunology | HIV Envelope Protein gp120 - immunology | Antibodies, Neutralizing - immunology | Receptors, CCR5 - metabolism | HIV Antibodies - immunology | Conserved Sequence | Inhibitory Concentration 50 | HIV Envelope Protein gp120 - chemistry | HIV Antibodies - pharmacology | Antibodies, Monoclonal - chemistry | Antibodies, Monoclonal - immunology | Cell Line | Immunoglobulin Fab Fragments - genetics | HIV-1 - drug effects | Antibodies, Monoclonal - pharmacology | Models, Molecular | Antibodies, Neutralizing - pharmacology | Antibody Affinity | Antibodies, Neutralizing - genetics | HIV Antibodies - chemistry | AIDS Vaccines - chemistry | Antibodies, Monoclonal - genetics | HIV-1 - immunology | Antibodies, Neutralizing - chemistry | Immunoglobulin Fab Fragments - chemistry | Cell Membrane - virology | Epitopes - chemistry | HIV Antibodies - genetics | Immunoglobulin Fab Fragments - immunology | CD4 Antigens - metabolism | Viral antibodies | Care and treatment | Antibodies | Physiological aspects | Genetic aspects | Research | HIV infection | Antigenic determinants | Amino acids | Mutation | Vaccines | Human immunodeficiency virus--HIV | Binding sites | Index Medicus
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 533, Issue 7601, pp. 105 - 109
...) infection, little progress has been made in generating an effective HIV-1 vaccine. Although passive transfer of anti-HIV-1 broadly neutralizing antibodies can protect... 
SIMIAN/HUMAN IMMUNODEFICIENCY VIRUS | POTENT | TRANSMISSION | HIV-1/SIV CHIMERIC VIRUS | BROADLY NEUTRALIZING ANTIBODY | MULTIDISCIPLINARY SCIENCES | IMPROVES PROTECTION | PASSIVE TRANSFER | MACAQUES | INFECTION | MONOCLONAL-ANTIBODIES | HIV Antibodies - blood | Antibodies, Neutralizing - administration & dosage | HIV Infections - prevention & control | AIDS Vaccines - immunology | Macaca mulatta - immunology | Half-Life | Male | Antibodies, Monoclonal - blood | HIV Infections - immunology | Macaca mulatta - virology | Antibodies, Neutralizing - immunology | Immunoglobulin Fc Fragments - immunology | HIV Antibodies - immunology | Time Factors | Female | HIV Infections - transmission | Antibodies, Monoclonal - immunology | Simian Immunodeficiency Virus - immunology | Protein Structure, Tertiary | SAIDS Vaccines - administration & dosage | Immunoglobulin Fc Fragments - chemistry | Antibodies, Neutralizing - genetics | Mutation - genetics | Simian Acquired Immunodeficiency Syndrome - blood | HIV Antibodies - administration & dosage | Simian Acquired Immunodeficiency Syndrome - prevention & control | Antibodies, Monoclonal - genetics | Animals | SAIDS Vaccines - immunology | Simian Acquired Immunodeficiency Syndrome - immunology | Antibodies, Monoclonal - administration & dosage | HIV Antibodies - genetics | AIDS Vaccines - administration & dosage | Immunoglobulin Fc Fragments - genetics | Antibodies, Neutralizing - blood | Prevention | Viral antibodies | Antibodies | Dosage and administration | HIV infection | Patient outcomes | Monoclonal antibodies | Immunoglobulins | Immunization | Vaccines | Human immunodeficiency virus--HIV | Viral infections
Journal Article
Current HIV research, ISSN 1570-162X, 2003
Journal
Nature immunology, ISSN 1529-2916, 2016, Volume 17, Issue 9, pp. 1102 - 1108
.... Here we investigated the serological cross-reaction between the two viruses. Plasma immune to DENV showed substantial cross-reaction to ZIKV and was able to drive antibody-dependent enhancement (ADE) of ZIKV infection... 
NEUTRALIZING ANTIBODIES | IMMUNOLOGY | CHIKUNGUNYA VIRUS | OUTBREAK | BRAZIL | BRAIN | Immunodominant Epitopes - immunology | Antibody-Dependent Enhancement | Epitope Mapping | Humans | Child, Preschool | Male | Antibodies, Viral - blood | Microcephaly - epidemiology | Antibodies, Monoclonal - blood | Antibodies, Neutralizing - immunology | South America - epidemiology | Immunodominant Epitopes - metabolism | Guillain-Barre Syndrome - epidemiology | Viral Envelope Proteins - metabolism | Female | Dengue - immunology | Child | Antibodies, Monoclonal - immunology | Zika Virus - physiology | Cells, Cultured | Dengue - epidemiology | Cross Reactions | Zika Virus Infection - epidemiology | Virus Replication | Adolescent | Protein Binding | Zika Virus Infection - immunology | Antibodies, Viral - immunology | Dengue Virus - physiology | Viral Envelope Proteins - immunology | Antibodies, Neutralizing - blood | Medical research | Immune response | Comorbidity | Dengue | Medicine, Experimental | Development and progression | Research | Observations | South America | Populations and Evolution | Viral Envelope Proteins | Zika Virus Infection | Microcephaly | Guillain-Barre Syndrome | Life Sciences | Computer Science | Genetics | Bioinformatics | Antibodies, Neutralizing | Parasitology | Quantitative Methods | Zika Virus | Antibodies, Monoclonal | Antibodies, Viral | Dengue Virus | Virology | Microbiology and Parasitology | Santé publique et épidémiologie | Immunodominant Epitopes | Human genetics
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2016, Volume 353, Issue 6301, pp. 823 - 826
Journal Article
Nature (London), ISSN 1476-4687, 2018, Volume 561, Issue 7724, pp. 479 - 484
.... Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1... 
SHIV INFECTION | PRIMARY HIV-INFECTION | RESERVOIR | DURABLE CONTROL | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | IN-VIVO | TREATMENT INTERRUPTION | T-CELLS | HUMANIZED MICE | Antibodies, Neutralizing - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Drug Resistance, Viral | Antibodies, Monoclonal - therapeutic use | Male | Phylogeny | Anti-HIV Agents - administration & dosage | Young Adult | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - adverse effects | HIV Antibodies - immunology | HIV-1 - isolation & purification | Antibodies, Neutralizing - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Antibodies, Neutralizing - adverse effects | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Antibodies, Monoclonal - immunology | Carrier State - immunology | HIV Infections - virology | Viremia - drug therapy | HIV Antibodies - administration & dosage | Carrier State - virology | HIV-1 - immunology | Viremia - virology | Antibodies, Monoclonal - administration & dosage | Viremia - prevention & control | Adolescent | Carrier State - drug therapy | HIV Infections - drug therapy | Viremia - immunology | Aged | HIV Envelope Protein gp160 - immunology | Infusions, Intravenous | Binding Sites, Antibody | Virus Activation - immunology | Virus Latency - immunology | Anti-HIV Agents - immunology | Drug Combinations | Physiological aspects | HIV patients | Care and treatment | Drug therapy, Combination | HIV antibodies | Antiretroviral drugs | Therapy | Antiviral agents | Interruption | Immunoglobulins | Viremia | Clinical trials | Viruses | Infections | Genomes | Antiretroviral therapy | Antiretroviral agents | Lymphocytes | Human immunodeficiency virus--HIV | Monoclonal antibodies | Drug therapy | Bioinformatics | Binding sites
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2011, Volume 334, Issue 6059, pp. 1097 - 1103
The HIV envelope (Env) protein gpl20 is protected from antibody recognition by a dense glycan shield... 
Polysaccharides | HIV | Neutralizing antibodies | RESEARCH ARTICLES | Antibodies | Viruses | Trimers | Epitopes | Grants | Binding sites | Crystal structure | PANEL | TRIMERS | MULTIDISCIPLINARY SCIENCES | IMMUNOGENS | ENVELOPE GLYCOPROTEIN COMPLEX | GP120 | HUMAN-IMMUNODEFICIENCY-VIRUS | MONOCLONAL-ANTIBODIES | TYPE-1 | Antibody Specificity | Mannose - immunology | Disaccharides - metabolism | Humans | Antibodies, Neutralizing - metabolism | Crystallography, X-Ray | Disaccharides - chemistry | Mannosides - chemistry | HIV Envelope Protein gp120 - metabolism | HIV Envelope Protein gp120 - immunology | Mannose - metabolism | Antibodies, Neutralizing - immunology | HIV-1 - physiology | HIV Antibodies - immunology | Immunoglobulin Fab Fragments - metabolism | Oligosaccharides - chemistry | Polysaccharides - chemistry | HIV Envelope Protein gp120 - chemistry | Mannose - chemistry | HIV Antibodies - metabolism | Protein Structure, Tertiary | Cell Line | Models, Molecular | Antibodies, Neutralizing - genetics | Glycosylation | Polysaccharides - immunology | Oligosaccharides - metabolism | HIV Antibodies - chemistry | Polysaccharides - metabolism | HIV-1 - immunology | Hydrogen Bonding | Antibodies, Neutralizing - chemistry | Immunoglobulin Fab Fragments - chemistry | Oligosaccharides - immunology | Protein Conformation | Mannosides - metabolism | HIV Antibodies - genetics | Immunoglobulin Fab Fragments - immunology | Mutation | Binding Sites, Antibody | Carbohydrate Conformation | Viral antibodies | Physiological aspects | Development and progression | Glycoproteins | HIV (Viruses) | Health aspects | Proteins | Antigens | Immunoglobulins | Human immunodeficiency virus--HIV
Journal Article